Skip to Content
Morningstar

Becton, Dickinson and Co BDX Stock Quote

Morningstar Rating
| Rating as of

Morningstar‘s Stock Analysis BDX

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Becton, Dickinson's 2022 Success Depends on Alaris

Alex Morozov, CFA Regional Director

Business Strategy and Outlook

| Alex Morozov, CFA |

While 2020 was a challenging year for Becton, Dickinson, or BD, 2021 has been better, buoyed by Veritor demand in particular. Much uncertainty resides in the return of BD's pump infusion system (Alaris) to the market, which could be a material catalyst for the company that will see some challenging comps as testing revenue wanes.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BDX

More

Company Profile BDX

Business Description

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Contact
1 Becton Drive
Franklin Lakes, NJ, 07417-1880
T +1 201 847-6800
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Jun 30, 2022
Fiscal Year End Sep 30, 2022
Employees 75,000

Related News BDX

Investing Specialists

Our Ultimate Stock-Pickers' Top 10 High-Conviction Purchases

Several funds see value in communication services and technology.
Eden Alemayehu
Market Update

The Winners of the New Definition of Infrastructure

Depending on which broader infrastructure projects take shape, numerous companies could see increased demand.
David Sekera
Stock Strategist Industry Reports

A Coronavirus Vaccine, or Three, Could Be Available by Year-End

We expect multiple approved vaccines by early 2021 with wide vaccine distribution in developed markets by mid-2021.
Karen Andersen
Stock Strategist Industry Reports

Slow Burn Likely Until Coronavirus Vaccines Are Widely Available

Resurgences in outbreaks make it clear that ending the pandemic will require more than diagnostic testing, contact tracing, and social distancing.
Karen Andersen
Our Picks

4 Dividend Stocks to Own

These stocks are among the top-10 holdings in several of our favorite dividend-growth funds.
Susan Dziubinski
US Videos

A Fast-Growing Slice of the Healthcare Sector for Your Radar

Life science and diagnostics firms offer attractive growth and moats, but be wary of valuations.
Michael Waterhouse
Fund Spy

A Thoughtful, Well-Researched Approach to Healthcare Investing

Silver-rated Fidelity Select Health Care's experienced manager takes a three-pronged approach to the sector.
Gregg Wolper
US Videos

M&A Activity Likely to Pick Up for Medical-Technology Firms

Becton Dickinson, Cardinal Health, and Abbott are all on track to make acquisitions.
Julie Utterback
Fund Times

Despite Manager Departure, This Fund Remains Appealing

Silver-rated Jensen Quality Growth is losing one of its skippers, but the fund has maintained its disciplined approach--and outperformance--through other departures.
Greg Carlson
Market Update

5 Investing Ideas From Top Dividend-Stock Fund Managers

Three fund managers share some dividend picks.
Manuela Badawy
Stock Analyst Update

Upgrading Our Growth Forecast for Becton, Dickinson

Across the firm, we are seeing the effects of significant R&D investments, with BD's pipeline the strongest it's been in our history of covering this narrow-moat medical technology company.
Alex Morozov
Fund Spy

Large-Growth Medalists at the Extremes of Sustainability

Quite a few good large-growth funds earn high Sustainability Ratings despite not being explicitly ESG-oriented.
David Kathman
Stock Strategist

Baxter's Headwinds Mostly Temporary

The company faces near-term challenges after the split, but we still like its moat.
Michael Waterhouse
Investing Specialists

Ultimate Stock-Pickers: Top Holdings of Top-Performing Managers

Our Ultimate Stock-Pickers Index continues to beat the market even as relatively few of our top managers are outperforming the S&P 500.
The Morningstar Ultimate Stock-Pickers Team
Fund Spy

Nominees for 2014 Domestic-Stock Fund Manager of the Year

Five candidates who did more than ride the market's currents.
Dan Culloton
Credit Insights

Robust Liquidity Returns to Corporate Bond Market

New issue market reaches new volume records
David Sekera
Credit Insights

Unusual Activity in 10-Year Treasury Hits Markets

Only best-known issuers with strong balance sheets dared tap the new issue market.
David Sekera
Credit Insights

Heightened Volatility Results in Sloppy Corporate Bond Trading

While marriages are increasing in the health-care sector, conscious uncoupling increases in the technology sector.
David Sekera
US Videos

2 Names to Gain From Industry Trends

A retailer's attractive pricing and a health-care firm's favorable prospects create solid growth opportunities for Jensen manager Eric Schoenstein.
Greg Carlson
Stock Strategist Industry Reports

Patient Trends Improving, but Reimbursement Outlook Remains Bleak for Health Service Providers

Greater accountability creates a new level of operating uncertainty.
Michael Waterhouse